At Avilar, we are moving beyond the boundaries of the cell to pioneer the discovery and development of extracellular protein degraders. Our ATACs (ASGPR Targeting Chimeras) are a new class of protein degrader therapeutics that shuttle disease-causing proteins from the circulation to the endolysosome where they are degraded.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.